A Boxed Warning concerning lactic acidosis was added to the label for Alogliptin and Metformin Hydrochloride, effective 2025-04-11. This serious adverse event has been linked to postmarketing cases resulting in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, making early detection challenging.
Background
Alogliptin and Metformin Hydrochloride is a combination medication. The Boxed Warning specifically addresses lactic acidosis, a known adverse event associated with the metformin component of the drug. Metformin is widely used, and while effective, its association with lactic acidosis is a critical safety consideration. Postmarketing surveillance has identified cases of metformin-associated lactic acidosis, underscoring the severity and potential for fatal outcomes. The warning details key clinical manifestations, including hypothermia, hypotension, and resistant bradyarrhythmias, which are important for clinicians to recognize.
What this means
The addition of a Boxed Warning to the label for Alogliptin and Metformin Hydrochloride represents a significant update to the drug's safety information. This emphasizes the critical importance for healthcare providers to be vigilant for signs and symptoms of lactic acidosis in patients receiving this medication. Clinicians should counsel patients on the potential risks and educate them on symptoms that warrant immediate medical attention. The warning highlights the need for careful patient selection, monitoring for risk factors, and prompt intervention if lactic acidosis is suspected. Given the often subtle onset and serious consequences, including death, understanding the clinical presentation of hypothermia, hypotension, and resistant bradyarrhythmias is paramount for timely diagnosis and management. This label revision serves to reinforce the seriousness of this potentially fatal adverse reaction associated with metformin-containing products and guides safer prescribing practices.
Source
This information regarding the label revision was obtained from the FDA. The update, effective 2025-04-11, is officially documented as a label revision in the dailyMed database, which is hosted by dailymed.nlm.nih.gov. This public record provides comprehensive drug information for healthcare professionals and researchers.